Cargando…

A bioinformatic analysis of WFDC2 (HE4) expression in high grade serous ovarian cancer reveals tumor-specific changes in metabolic and extracellular matrix gene expression

Human epididymis protein-4 (HE4/WFDC2) has been well-studied as an ovarian cancer clinical biomarker. To improve our understanding of its functional role in high grade serous ovarian cancer, we determined transcriptomic differences between ovarian tumors with high- versus low-WFDC2 mRNA levels in Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	James, Nicole E., Gura, Megan, Woodman, Morgan, Freiman, Richard N., Ribeiro, Jennifer R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107348/ https://www.ncbi.nlm.nih.gov/pubmed/35568777 http://dx.doi.org/10.1007/s12032-022-01665-4

Ejemplares similares

HE4 (WFDC2) gene overexpression promotes ovarian tumor growth
por: Moore, Richard G., et al.
Publicado: (2014)

Intratumoral expression analysis reveals that OX40 and TIM-3 are prominently expressed and have variable associations with clinical outcomes in high grade serous ovarian cancer
por: James, Nicole E., et al.
Publicado: (2022)

HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines
por: Li, Jinping, et al.
Publicado: (2013)

Immune Modeling Analysis Reveals Immunologic Signatures Associated With Improved Outcomes in High Grade Serous Ovarian Cancer
por: James, Nicole E., et al.
Publicado: (2021)

Modulated expression of WFDC1 during carcinogenesis and cellular senescence
por: Madar, Shalom, et al.
Publicado: (2009)

WFDC Protein: A Promising Diagnosis Biomarker of Ovarian Cancer
por: Zhang, Chen, et al.
Publicado: (2021)

Prognostic Significance of HE4 Tissue Expression in Serous Epithelial Ovarian Carcinoma
por: Sethi, Ankita, et al.
Publicado: (2022)

The Role of the Extracellular Matrix and Tumor-Infiltrating Immune Cells in the Prognostication of High-Grade Serous Ovarian Cancer
por: Belotti, Yuri, et al.
Publicado: (2022)

The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes
por: James, Nicole E., et al.
Publicado: (2020)

Prognostic gene expression signature for high-grade serous ovarian cancer
por: Millstein, J., et al.
Publicado: (2020)

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma
por: Norris, Eric J, et al.
Publicado: (2019)

Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer
por: Zhao, Li, et al.
Publicado: (2022)

Low-grade serous carcinoma with extensive osseous metaplasia arising from ovarian serous cystadenofibroma
por: Ribeiro e Ribeiro, Renan, et al.
Publicado: (2021)

Similar protein expression profiles of ovarian and endometrial high-grade serous carcinomas
por: Hiramatsu, Kosuke, et al.
Publicado: (2016)

WFDC2 (HE4): A potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung
por: Bingle, Lynne, et al.
Publicado: (2006)

Increased levels of HE4 (WFDC2) in systemic sclerosis: a novel biomarker reflecting interstitial lung disease severity?
por: Zhang, Mingxia, et al.
Publicado: (2020)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

Integrative evaluation and experimental validation of the immune-modulating potential of dysregulated extracellular matrix genes in high-grade serous ovarian cancer prognosis
por: Wu, Qihui, et al.
Publicado: (2023)

Bioinformatics analysis of gene expression profile of serous ovarian carcinomas to screen key genes and pathways
por: Fei, Hongjun, et al.
Publicado: (2020)

PAX2 Expression in Low Malignant Potential Ovarian Tumors and Low-Grade Ovarian Serous Carcinomas
por: Tung, Celestine S., et al.
Publicado: (2009)

Identification of Chemoresistance-Associated Key Genes and Pathways in High-Grade Serous Ovarian Cancer by Bioinformatics Analyses
por: Wu, Yong, et al.
Publicado: (2020)

Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers
por: Bischof, Katharina, et al.
Publicado: (2019)

Adaptive transcriptomic and immune infiltrate responses in the tumor immune microenvironment following neoadjuvant chemotherapy in high grade serous ovarian cancer reveal novel prognostic associations and activation of pro-tumorigenic pathways
por: James, Nicole E., et al.
Publicado: (2022)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

Extracellular microRNA profiling for prognostic prediction in patients with high‐grade serous ovarian carcinoma
por: Yoshida, Kosuke, et al.
Publicado: (2021)

Identifying high-grade serous ovarian carcinoma–specific extracellular vesicles by polyketone-coated nanowires
por: Yokoi, Akira, et al.
Publicado: (2023)

High WFDC3 gene expression is associated with poor prognosis and reduced immune cells infiltration in pancreatic adenocarcinoma: A study using the TCGA database and bioinformatics analysis
por: Wu, Wei, et al.
Publicado: (2023)

Tubal Origin of “Ovarian” Low-Grade Serous Carcinoma: A Gene Expression Profile Study
por: Wang, Yiying, et al.
Publicado: (2019)

VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer
por: Zong, Liju, et al.
Publicado: (2019)

Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer
por: Tan, Jiahong, et al.
Publicado: (2021)

Low Expression of RGS2 Promotes Poor Prognosis in High-Grade Serous Ovarian Cancer
por: Ihlow, Jana, et al.
Publicado: (2022)

Clinical significance of SPOCK2 expression signature for high-grade serous ovarian cancer patients
por: Jiao, Mi, et al.
Publicado: (2022)

Changes in Nucleolin Expression during Malignant Transformation Leading to Ovarian High-Grade Serous Carcinoma
por: Paris, Elizabeth A., et al.
Publicado: (2023)

First-Line Management of Advanced High-Grade Serous Ovarian Cancer
por: Mahmood, Reem D., et al.
Publicado: (2020)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Differential expression of argininosuccinate synthetase in serous and non‐serous ovarian carcinomas
por: Cheon, Dong‐Joo, et al.
Publicado: (2014)

WFDC21P promotes triple-negative breast cancer proliferation and migration through WFDC21P/miR-628/SMAD3 axis
por: Wei, Yu-Bo, et al.
Publicado: (2022)

Targeting the Microenvironment in High Grade Serous Ovarian Cancer
por: Nwani, Nkechiyere G., et al.
Publicado: (2018)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cjuj07tu8m0tjsiqbmcgma4h61